• No results found

ANCA-associated vasculitis : towards patient-tailored therapy Berden, A.E.

N/A
N/A
Protected

Academic year: 2021

Share "ANCA-associated vasculitis : towards patient-tailored therapy Berden, A.E."

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

ANCA-associated vasculitis : towards patient-tailored therapy

Berden, A.E.

Citation

Berden, A. E. (2011, October 13). ANCA-associated vasculitis : towards patient-tailored therapy. Retrieved from https://hdl.handle.net/1887/17938

Version: Corrected Publisher’s Version License:

Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/17938

Note: To cite this publication please use the final published version (if applicable).

(2)

ANCA-associated vasculitis:

towards patient-tailored therapy

Annelies Evaline Berden

(3)

ANCA-associated vasculitis: towards patient-tailored therapy

Thesis, Leiden University, Leiden, the Netherlands

© A.E. Berden, 2011, Leiden, the Netherlands

Used with permission:

Chapter 2 © BMJ Publishing Group Ltd., Annals of the Rheumatic Diseases Chapter 5 © John Wiley and Sons, Arthritis & Rheumatism

Chapter 6 © ASN, Journal of the American Society of Nephrology Chapter 7 © ASN, Journal of the American Society of Nephrology

No part of this thesis may be reproduced, stored or transmitted in any form or by any means, without prior written permission of the author.

Printing: Gildeprint Drukkerijen - Enschede, the Netherlands Cover design and illustrations: Willemijn Huijgen

ISBN: 978-90-9026342-7

(4)

ANCA-associated vasculitis:

towards patient-tailored therapy

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnificus prof. mr. P.F. van der Heijden, volgens besluit van het College voor Promoties

te verdedigen op donderdag 13 oktober 2011 klokke 15.00 uur

door

Annelies Evaline Berden

geboren te Rotterdam in 1985

(5)

PROMOTIECOMMISSIE

Promotor: Prof. dr. J.A. Bruijn Co-promotores: Dr. I.M. Bajema

Dr. E.C. Hagen

Meander Medisch Centrum, Amersfoort

Overige leden: Prof. dr. A.J. Rabelink Prof. dr. R.M. Bertina Prof. dr. C.G.M. Kallenberg

Universitair Medisch Centrum Groningen

The studies described in this thesis were performed at the Department of Pathology (head: Prof. Dr. G.J. Fleuren) of the Leiden University Medical Center, Leiden, the Netherlands.

The printing of this thesis was financially supported by: Astellas Pharma B.V., Friedrich Wegener Stichting, Genzyme Nederland, J.E. Jurriaanse Stichting, Novartis Pharma B.V., Reumafonds, Roche Nederland B.V.

(6)

We zijn allang begonnen, maar nu begint het echt.

Joke van Leeuwen

Aan mijn ouders en Barry

(7)
(8)

CONTENTS

C

hapter

1 G

eneralintroduction

C

hapter

2 l

onG

-

termpatient survivalin

anca-

associated

vasculitis

C

hapter

3 p

redictorsoflonG

-

term

(≥ 5

yr

)

renal survivalin

535

patientswith

anca-

associatedvasculitis

C

hapter

4 t

celltubulitisandtubularatrophypredictrenal

outcomein

anca-

associatedGlomerulonephritis followinGrituximabtherapy

C

hapter

5 c

ellularimmunityin

w

eGener

s

G

ranulomatosis

:

characterizinG

t

lymphocytes

C

hapter

6 a

nti

-

plasminoGenantibodiescompromisefibrinolysis

andassociatewithrenalhistoloGyin

anca-

associatedvasculitis

C

hapter

7 h

istopatholoGicclassificationof

anca-

associated

Glomerulonephritis

C

hapter

8 s

ummaryandGeneraldiscussion

C

hapter

9 n

ederlandsesamenvattinG

a

ppendix

a a

uthorsandaffiliations

a

ppendix

B c

urriculumvitae

a

ppendix

C l

istofpublications

a

ppendix

d d

ankwoord

(a

cknowledGements

)

9 59

79

101

121

145

177

199 211

229 225

233 235 –

(9)

Referenties

GERELATEERDE DOCUMENTEN

the NoRAM trial was designed to investigate if methotrexate could replace standard therapy with cyclophosphamide as induction treatment of patients with newly di- agnosed,

21 This study assessed the long-term survival and factors predicting mortality in patients with ANCA-associated vasculitis who par- ticipated in four randomized trials organized

the predictive value of entry eGFR and renal relapse with respect to long-term renal survival reported in this study, underlines the importance of an early diagnosis and

19;20 Our data add that both tubular intraepithelial B cells (markers CD79a and CD20) and tubular intraepithelial T cells are present in biopsies of patients with AAV, but that

Anti-plasminogen antibodies isolated from PR3-ANCA vasculitis patients in a North American cohort seem to recognize an epitope within the protease domain, but again these

As depicted in Table 3 and Figure 3, the renal biopsy categories were correlated to the degree of renal function at presentation and at 1- and 5-year follow-up (all p ≤ 0.001),

Newer therapies, such as rituximab, first showed promising results in patients with refractory disease, unresponsive to standard therapy regimens, but were recently demonstrated

Cellulaire afweer: T-celeigenschappen in ANCA-geassocieerde vasculitis Hierboven werd beschreven dat rituximab een veelbelovend geneesmiddel is, niet alleen als behandeloptie